Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Topically Delivered FS2 (Kynurenic Acid) in Healthy Volunteers
NCT02340325Phase 1Completed
- Sponsor
- BC Professional Firefighters' Burn and Wound Healing Laboratory
- Start
- May 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Fibrostop in Hypertrophic Scar (HS) and keloid (2 arms), sponsored by BC Professional Firefighters' Burn and Wound Healing Laboratory. Primary endpoint: Acute skin irritation or local reaction at 24 hours. Started May 2015; status: completed.
02
Drugs
Fibrostop
03
Conditions
Hypertrophic Scar (HS)keloid
Beyond the preview
Go deeper on NCT02340325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340325.